359 related articles for article (PubMed ID: 17419802)
1. Use of proteomics for the identification of novel drug targets in brain diseases.
Morón JA; Devi LA
J Neurochem; 2007 Jul; 102(2):306-15. PubMed ID: 17419802
[TBL] [Abstract][Full Text] [Related]
2. How proteomics reveals potential biomarkers in brain diseases.
Schmidt O; Schulenborg T; Meyer HE; Marcus K; Hamacher M
Expert Rev Proteomics; 2005 Dec; 2(6):901-13. PubMed ID: 16307519
[TBL] [Abstract][Full Text] [Related]
3. Functional Genomics meets neurodegenerative disorders. Part II: application and data integration.
Hoerndli F; David DC; Götz J
Prog Neurobiol; 2005 Jun; 76(3):169-88. PubMed ID: 16169146
[TBL] [Abstract][Full Text] [Related]
4. Avian proteomics: advances, challenges and new technologies.
Doherty MK; McLean L; Beynon RJ
Cytogenet Genome Res; 2007; 117(1-4):358-69. PubMed ID: 17675879
[TBL] [Abstract][Full Text] [Related]
5. Proteomics: recent applications and new technologies.
Elrick MM; Walgren JL; Mitchell MD; Thompson DC
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):432-41. PubMed ID: 16635100
[TBL] [Abstract][Full Text] [Related]
6. Complementary methods to assist subcellular fractionation in organellar proteomics.
Gauthier DJ; Lazure C
Expert Rev Proteomics; 2008 Aug; 5(4):603-17. PubMed ID: 18761470
[TBL] [Abstract][Full Text] [Related]
7. Blood-brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling brain drug delivery.
Calabria AR; Shusta EV
Drug Discov Today; 2006 Sep; 11(17-18):792-9. PubMed ID: 16935746
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional drugs with different CNS targets for neuropsychiatric disorders.
Van der Schyf CJ; Geldenhuys WJ; Youdim MB
J Neurochem; 2006 Nov; 99(4):1033-48. PubMed ID: 17054441
[TBL] [Abstract][Full Text] [Related]
9. Advances in neuromembrane proteomics: efforts towards a comprehensive analysis of membrane proteins in the brain.
Grant KJ; Wu CC
Brief Funct Genomic Proteomic; 2007 Mar; 6(1):59-69. PubMed ID: 17353200
[TBL] [Abstract][Full Text] [Related]
10. Proteomics: present and future implications in neuro-oncology.
Micallef J; Gajadhar A; Wiley J; DeSouza LV; Michael Siu KW; Guha A
Neurosurgery; 2008 Mar; 62(3):539-55; discussion 539-55. PubMed ID: 18425004
[TBL] [Abstract][Full Text] [Related]
11. Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking.
Zabel C; Sagi D; Kaindl AM; Steireif N; Kläre Y; Mao L; Peters H; Wacker MA; Kleene R; Klose J
J Proteome Res; 2006 Aug; 5(8):1948-58. PubMed ID: 16889417
[TBL] [Abstract][Full Text] [Related]
12. Proteome analysis of the dorsolateral prefrontal region from healthy individuals.
Alexander-Kaufman K; Dedova I; Harper C; Matsumoto I
Neurochem Int; 2007; 51(6-7):433-9. PubMed ID: 17590479
[TBL] [Abstract][Full Text] [Related]
13. Neuroproteomics - the tasks lying ahead.
Becker M; Schindler J; Nothwang HG
Electrophoresis; 2006 Jul; 27(13):2819-29. PubMed ID: 16739225
[TBL] [Abstract][Full Text] [Related]
14. Neuroproteomics of the synapse and drug addiction.
Abul-Husn NS; Devi LA
J Pharmacol Exp Ther; 2006 Aug; 318(2):461-8. PubMed ID: 16644901
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder.
Gogos JA
Int Rev Neurobiol; 2007; 78():397-422. PubMed ID: 17349868
[TBL] [Abstract][Full Text] [Related]
16. Subcellular proteomics.
Dreger M
Mass Spectrom Rev; 2003; 22(1):27-56. PubMed ID: 12768603
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches to the study of postmortem brain in psychiatric illness: old limitations and new challenges.
McCullumsmith RE; Meador-Woodruff JH
Biol Psychiatry; 2011 Jan; 69(2):127-33. PubMed ID: 21094488
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective.
Alvarez-Llamas G; de la Cuesta F; Barderas ME; Darde V; Padial LR; Vivanco F
Expert Rev Proteomics; 2008 Oct; 5(5):679-91. PubMed ID: 18937558
[TBL] [Abstract][Full Text] [Related]
19. Yeast genomics and proteomics in drug discovery and target validation.
Parsons AB; Geyer R; Hughes TR; Boone C
Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
[TBL] [Abstract][Full Text] [Related]
20. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
Ekegren T; Hanrieder J; Bergquist J
J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
